Risk of HCV infection associated with hospital-based invasive procedures: a systematic review and meta-analysis

Paul Henriot[1,2], Mathieu Castry[3], Liem Binh Luong Nguyen[4], Yusuke Shimakawa[2,5], Kévin Jean[1,2], Laura Temime[1,2]

[1]MESuRS Laboratory, Conservatoire national des arts et métiers, 292 rue Saint-Martin, 75003, Paris

[2]PACRI Unit, Conservatoire national des arts et métiers / Institut Pasteur, France

[3]Université de Paris, Inserm, IAME, F-75006 Paris, France

[4]CIC Cochin, AP-HP, Paris

[5]Unité d'Epidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France

Correspondence to : Paul Henriot, Conservatoire national des arts et métiers (MESuRS Laboratory), 292 rue Saint-Martin, 75003, Paris. **Email address :** paul.henriot@lecnam.net

Summary

Background: Healthcare settings, where invasive procedures are frequently performed, may play an important role in the transmission dynamics of blood-borne pathogens when compliance with infection control precautions remains suboptimal. This study aims at better understanding and quantifying the role of hospital-based invasive procedures on hepatitis C virus (HCV) transmission.

Methods: We conducted a systematic review and meta-analysis to identify recent studies reporting association measures of HCV infection risk that are linked to iatrogenic procedures performed in hospital settings. Based on expert opinion, invasive procedures were categorized into 10 groups for which pooled measures were calculated. Finally, the relationship between pooled measures and the country-level HCV prevalence or the Healthcare Access and Quality (HAQ) index was assessed in meta-regressions.

Findings: A total of 71 studies were included in the analysis. The most frequently evaluated procedures were blood transfusion and surgery (60 and 37 studies, respectively). The pooled odds ratio (OR) of HCV infection varied widely, ranging from 1·46 (95%CI: 1·14-1·88) for dental procedures to 3·84 (2·07-7·12) for wound care. The OR for blood transfusion was higher for transfusions performed before 1998 (3·77, 2·42-5·88) than for those without a specified date (2·26, 1·81-2·81). Finally, the country-level overall risk for all procedures was significantly associated with HCV prevalence, but not with the HAQ index. In procedure-specific analyses, the HCV infection risk was significantly negatively associated with the HAQ for endoscopy and positively associated with HCV prevalence for endoscopy and surgery.

Interpretation: Various invasive procedures were documented to be significantly associated with HCV infection. Our results provide a ranking of procedures in terms of HCV risk that may be used for prioritization of infection control measures, especially in high HCV prevalence settings.

Funding: INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hépatites)

Research in context

Evidence before this study

We searched PubMed for systematic review or meta-analyses articles published between Jan 1, 2000 and Oct 31, 2021, and focused on iatrogenic risk factors associated with HCV infection in hospitalized patients, using "hepatitis C", "risk" and "hospital" as keywords. We found a single comprehensive meta-analysis assessing HCV risk factors and reporting pooled risks estimates for hospital-based procedures. However, this meta-analysis was not specific to in-hospital procedures, based on articles published between 1989 and 2013, and did not strictly follow the PRISMA guidelines.

Added value of this study

Our study presents an up-to-date assessment of the risks of HCV infection associated with different hospital-based procedures. Results suggest that iatrogenic HCV infection risk remains important, in studies that were recently conducted. We underline the importance of this risk in high prevalence settings and provide a potential prioritization of procedures associated with HCV infection that may help implementing infection control measures efficiently.

Implications of all the available evidence

This study shows that iatrogenic procedures remain at risk of transmitting blood-borne pathogens, in particular HCV. Despite the availability of highly efficacious direct acting antivirals to treat chronic HCV infection, the prevention of iatrogenic HCV infection, through strictly complying with the established standard precautions, remains essential. These results could be used in modelling studies to help find optimal and efficient control measures to reduce in-hospital HCV transmission.

Introduction

Hepatitis C virus (HCV) is mainly a blood-borne virus associated with an estimated global sero-prevalence of 2.5%.[1] However, wide between-country discrepancies are observed, with Egypt and Pakistan having high anti-HCV prevalence in the general population.[1] Chronic HCV infection may lead to serious complications like cirrhosis or hepatocellular carcinoma (HCC), with about 20% developing HCC.[2] Highly effective and well-tolerated direct-acting antiviral treatments (DAAs) are now available, but these treatments remain costly. An estimated 79% of people chronically infected with HCV worldwide still did not know their status in 2019,[3] limiting the population impact of DAAs. In addition, the residual risk of HCC is suspected to remain relatively high among patients who cured chronic HCV infection.[4] Moreover, HCV treatment should not be the only way of fighting new infections, as accumulating evidence suggests that even after the DAA therapy-induced sustained virological response (SVR) reinfection can occur, especially in people who inject drugs.[5] Therefore, prevention measures to limit the risk of HCV contamination remain key in the global response against HCV.[6]

Although injection drug use has been established to be the most important risk factor for acquiring a new HCV infection,[7] healthcare settings may play an important role in HCV transmission dynamics, due to the high frequency of invasive procedures and over-representation of HCV-infected individuals among hospitalized patients. Medical procedures have been linked to multiple HCV outbreaks worldwide, for instance in Egypt[8], India[9] or the United States.[10] In healthcare settings where compliance with infection control measures is suboptimal, patients may still become infected following blood transfusion or haemodialysis.[11,12] Previous hospitalization has been identified as a major risk factor for HCV infection in many countries[13].

In this context, a better control of hospital-acquired infections would significantly help in the fight against HCV epidemics. This requires a clear understanding of the role played by different at-risk procedures within healthcare settings, in order to effectively focus control measures and efforts. Here, we conduct a systematic review and meta-analysis of the current evidence regarding the strength of association between HCV infection and a wide array of hospital-based invasive procedures, in order to propose a prioritization of iatrogenic procedures and better understand their role in HCV transmission.

Methods

Search strategy and selection criteria

We searched three online databases (PubMed, Web of Science, Scopus) for studies published between January 2000 and December 2020 using the keywords "hepatitis", "risk factor", "hospital", and "procedure" as main lexical fields (Suppl Table S1). This study was registered in PROSPERO in February 2021 (ID: CRD42021224886), and is reported according to PRISMA guidelines.

Studies were eligible if: (i) Exposure group was composed of adults, either in or out-patients; (ii) they reported measures of association (odds ratios, ORs; risk ratios, RRs; or prevalence ratios, PRs) by comparing the proportion of people positive for HCV RNA or anti-HCV antibody between a group who underwent a specific health-care procedure and another group not exposed to the procedure. There was no restriction in terms of the study design.

Studies were excluded if: (i) They were focused on paediatric patients, drug users, or blood donors only, to avoid bias linked to either age-constraint or repetitive at-risk habits; (ii) patient inclusion started before 2000; (iii) they were not written in French or English; (iv) they did not present original results.

Based on the inclusion and exclusion criteria, articles titles and abstracts were screened by two
independent investigators (MC and PH) using the Covidence review tool.[14] Full-text articles were then
retrieved and assessed for eligibility by the same two authors. Any conflict in articles screening or full-
text assessment were resolved by a third senior researcher (KJ or LT).

For each study, the following data were extracted by PH: (i) Total number of patients; (ii) patients type;
(iii) study design; (iv) measures of association and sample size of the control/exposed groups

Data analysis

After studies selection, the procedures reported were aggregated into 10 groups based on medical
expert opinion (Table 1). Risk of blood borne infection was supposed to be the same within these
groups. When two or more procedures classified in the same group were assessed within the same
study, a pooled group-level measure was computed using a fixed-effect model since these estimates
were calculated based on the same population. Measures associated with the same procedure but
reported across different populations (e.g., by gender) were considered independently.

We performed a meta-analysis to compute pooled OR estimates of the risk of HCV infection associated
with each procedure group using the R "meta" package.[15] Procedure-specific forest plots were visually
inspected for potential outliers. Measures that were not ORs (RRs and PRs) were considered to be
equivalent to ORs and included in the same analyses. When both adjusted ORs (AORs) and crude ORs
(CORs) were available in the same study, the AORs were preferred. In a same study, if risk estimates
were available for dated and undated (without specified date) blood transfusion, estimates associated
with undated blood transfusion were preferred.

In a second step, pooled ORs for low HCV prevalence (< 5%) and high HCV prevalence (> 5%) countries
were compared through subgroups analysis for each procedure group. Prevalence data for each
country were collected from the MapCrowd online global data on hepatitis C (Suppl Table S7).[16] Pooled
ORs were stratified by country for the 2 most represented procedure groups. In addition, subgroups
analyses were performed to compare estimates between cohort and non-cohort studies.

Thirdly, the pooled OR for blood transfusion based on transfusions performed with either recent dated
or an unspecified date of realization was compared to the one based on transfusions performed before
1998, which is the latest cut-off date used within selected articles. We assumed cut-off dates found in
the studies selected to reflect local implementation of mandatory HCV screening in blood donors.

Finally, meta-regressions were performed to investigate the potential effect modifier of: (i) the HCV
prevalence level, and (ii) the Healthcare access and quality (HAQ) index, a 0 to 100 score quantifying
the strength of healthcare quality and access based on amenable mortality data in each country (Suppl
Table S7).**[17]**

Pooled estimates were computed using random effect models considering our aim to generalize results
beyond the selected studies. Each of these estimates was calculated together with the heterogeneity
level (I^2 statistics). Comparisons were performed using Cochran's Q test.[18]

The risk of bias was assessed by PH on the articles included. Nine bias assessment criteria were adapted
from Lam *et al.* (2016c)[19], and publication bias was assessed by testing for asymmetry in the overall
and procedure-specific funnel plots.[19]

Role of the funding source

Results

Among the 1,961 initially identified studies, 71 were included in the review and meta-analysis[21-91], as
described in the flow diagram (Fig. 1). The total number of participants across all selected studies was
120,734.

Fig. 2.a shows an increase in publications related to HCV risk assessment within hospitals between
2000 and 2015, while the number of publications remained stable between 2015 and 2020. Together,
Pakistan (fourteen studies) and Egypt (nine studies) represented one third of all included studies
(Fig2.c). Over a fifth of studies were focused on haemodialysis patients (21·9%) (Fig. 2.b). Most studies
were cross-sectional (55%) or case-control (22·5%) studies (Fig. 2d).

Forty-five different procedures were assessed (Table 1). The number of observations per each of the
ten procedure groups ranged from five to sixty, with surgery and transfusion as the largest groups
(respectively 37 and 60) (Fig. 3, Suppl Table S6). Visual inspection of procedure-specific forest plots
(Suppl Fig. S6 to S15) led to the exclusion of a single outlier for haemodialysis (Suppl Fig. S6).

All pooled ORs were significantly superior to one, except for endoscopy and haemodialysis.

Procedure-specific analyses showed that the risk of HCV infection differed significantly according to
procedure groups (Q = 22·48, p < 0·01), with pooled OR estimates ranging from 1·46 (CI 95% [1·14-
1·88]) for dental procedure up to 3·84 (CI 95% [2·07-7·12]) for wound care. The IV/Catheter, wound
care and transplantation groups had OR estimates ranging from 2·86 (CI 95% [1·66-4·93] for
IV/Catheter) to 3·84 (CI 95% [2·07-7·12] for wound care), representing moderate/high risk groups. The
haemodialysis, surgery, other procedure, and transfusion groups had intermediate pooled ORs, with
estimates of 2·02 (CI 95% [0·98-4·17]), 2·21 (CI 95% [1·75-2·8]), 2·22 (CI 95% [1·3-3·77]),2·6 (CI 95%
[2·1-3·22]) respectively. Injection was associated with a low/moderate risk of HCV infection with an
estimate of 1·69 (CI 95% [1·19-2·41]). Finally, the dental procedure and endoscopy groups presented
the lowest risks of getting HCV infected (1·46 CI 95% [1·14-1·88] and 1·48 CI 95% [0·95-2·30]
respectively).

Country-stratified analyses were performed for transfusion and surgery (Fig. 4). For these two
procedure groups, estimated ORs varied widely between countries. The highest risk of HCV infection
by blood transfusion was reported in Germany (OR = 5·39 CI 95% [2·67-10·89]) but this estimate
corresponds to only one study and is associated with transfusions performed before 1991. Other
countries associated with relatively high HCV infection average risk for blood transfusion were Egypt
(OR = 5·16 CI 95% [1·86-14·28]), Iran (5·11 [1·04-24·99]), Turkey (4·50 [1·71-11·86]) and Malaysia (4
[2·18-7·35]). Nevertheless, associated confidence intervals were quite wide. There were less high-risk
countries concerning surgery, for which Egypt and India were associated with the highest risk (4·27
[2.03-8·98] and 4·62 [0·82-26·02]).

Overall, average estimates were always higher in high prevalence countries (Fig. 5) though this
difference was not significant (Q=2·11, p=0·15), Nevertheless, a significant difference was observed for
endoscopy (Q=9·40, p-value=0·002), surgery (Q=4·54, p-value=0·03) and injection (Q=5·40, p =0·02).
These results were supported by procedure-specific meta-regressions (Suppl Table S3) showing
prevalence to have a significant positive effect on the OR level of the endoscopy (p < 0·01) and surgery
(p=0·011) groups. Prevalence was also found to have a significant positive effect on the risk of
iatrogenic HCV infection as a whole (p < 0·01, Suppl Table S5). On the contrary, no overall association
was found between HAQ level and risk of iatrogenic infection, while in procedure-specific analyses a
negative significant impact of the HAQ level was observed for endoscopy only (p=0·02, Suppl Table S4).

For blood transfusions performed before 1998, 17 studies were selected for the pooled OR calculation,
whereas there were 48 studies available for undated blood transfusions (Suppl Fig. S3 and S4). The
estimated pooled OR of HCV infection associated with blood transfusions performed before 1998 (OR
= 3·77 CI 95% [2·42-5·88]) was significantly higher than the pooled OR associated with undated blood
transfusions (2·28 [1·82-2·84], p = 0·05, Q =3·97)

Across all studies, bias was low for most criteria, but some studies presented a potentially high risk of
bias for criteria related to exposure assessment and to potential confounding (Suppl Fig.S1 and Suppl
Table S2). No single study had high bias risk for all criteria. Nevertheless, the overall funnel plot showed
asymmetry and the associated Egger test was highly significant, suggesting potential publication bias
(Suppl Fig. S2).

Average ORs in non-cohort studies were found to be higher than in cohort studies (2·26 CI 95% [1·98-
2·57] vs. 1·92 [1·47-2·50]) but this difference was not significant (Q = 1·16, p = 0·28). Per-procedure
comparisons between cohort and non-cohort studies only showed a significant difference for the
transplantation (Q = 6·32, p = 0·01) and the injection (Q = 4·62, p = 0·03) group, for which cohort studies
was found to be associated with lower estimates.

Discussion

In this systematic review and meta-analysis, we identified 71 studies assessing the association between
hospital-based invasive procedures and the risk of HCV infection, representing a total of 120,734
participants. The overall strength of evidence remained of limited confidence as the bias analysis found
a lack of high-quality studies. Nevertheless, we estimated pooled ORs of HCV infection that were
significantly associated with most invasive procedures performed in hospitals. Our results suggest a
prioritization of iatrogenic procedures: wound care was associated with the highest risk of HCV
infection whereas dental procedures and endoscopy were associated with the lowest risk. We also
underlined a large between-procedure and between-country variability, and showed that the per-
procedure risk tended to be higher in countries with high HCV prevalence, while the level of healthcare
quality and access in the country (as measured by the HAQ) only appeared to play a minor role.

The geographical coverage of selected studies was in line with global observed prevalence levels, with
a third of these studies coming from the two countries with the highest HCV prevalence worldwide
(Egypt and Pakistan). In addition, the most represented population was composed of haemodialyzed
patients, for which the risk of HCV infection is historically susbtantial.[92] Regrettably, only few studies
used cohort data.

The estimated per-procedure risks seemed to be mostly in line with the available literature concerning
HCV. Generally, the risk was higher for procedures with frequent blood-contact.

Surprisingly, we found that the highest risk of infection was found for wound care. The estimate of the
HCV infection risk through sutures found in the only previous meta-analysis by El Ghitany et al. was
lower than our estimate, but increased in the most recent studies.[13]

The risk associated with organ transplantation was found to be quite high, considering that most of
countries now require HCV testing in donors.[92] This might result from either lack of information on the
procedure realization date or the type of study design used to assess this risk, as it was found to be
much lower considering only cohort studies. Similarly, the intermediate risk we found for blood
transfusion could be explained by the fact that there is still high discrepancy in systematic screening of
blood products between countries (only 80% of donations are screened in low-income countries).[93]

Haemodialysis was also associated with an intermediate risk of HCV infection. Our estimate was within
the same order of magnitude than the one reported in the previous meta-analysis.[13]

We found injection to be one of the lowest at-risk procedures. Iatrogenic injection was described in
the past as associated with a high risk of HCV infection, in particular because of the reuse of
contaminated syringes,[8] but this risk might have dropped over the last decade, in particular after the
publication of multiple WHO and CDC guidelines for safe injections.[94]

Finally, dental procedures and endoscopy were found to be the lowest risk groups, in line with current
literature findings. Indeed, only a few cases of HCV contamination after endoscopy have been
described and dental practices are often at low risk of contamination.[92,95] This result is also consistent
with previous estimations showing low risk associated with these two procedures.[13]

Country-level prevalence was overall found to be related to a higher risk of HCV contamination,
although it was only significantly associated with endoscopy and surgery risks when looking at specific
procedures. The lack of significance for other procedures may be explained in several ways. First, many
countries were represented by less than 3 studies, leading to a lack of power for some procedures and
countries and less accurate OR estimates. Second, these non-significant associations may also indicate
the presence of other causes of heterogeneity. In particular, there may be high differences in terms of
prevalence between hospital settings within the same country. Observed between-country variations
may also result from different infection control practices; we explored this assumption using the HAQ
index, which is internationally validated and available for all countries in our analysis. However, we
found no significant relationship between the risk of getting HCV contaminated and this index, except
for the risk linked to endoscopy. First, the HAQ index may not be the right indicator to accurately reflect
compliance with infection control measures within hospitals. Second, there could be a high
heterogeneity in this compliance between settings within the same country, that this index is unable
to capture.

Our study carries several methodological as well as more study-related limitations.

First, no grey literature or papers in languages other than French or English were included in this
review, resulting in a potential information loss. Some other methodological simplifications could have
influenced our final results. In fact, pooling adjusted and non-adjusted measures could have led to
overestimation of risks associated with some procedures. Our results also highly depend on the initial
procedures classification we proposed, which may contribute to the high between-study
heterogeneity we observed for many procedure groups. However, this classification was necessary due
to the overall high number of unique procedures identified in the review. Moreover, the high
heterogeneity could also result from other sources (e.g., prevalence or infection control).

This study highlighted several caveats in the existing literature. Bias analysis showed a lack of high-
quality studies. On the one hand, 90% of studies presented at least a probably high bias concerning
the assessment of exposure to hospital-based procedures, mostly using questionnaires to collect risk
factors for HCV infection. This is consistent with the distribution of studies design, since almost 80% of
studies were either cross-sectional or case-control studies. This over-representation of non-
longitudinal designs may in particular have led to overestimated ORs of HCV infection associated with
invasive iatrogenic procedures, due to differential recall bias between cases and controls. We
investigated this through a separate assessment of pooled ORs in non-cohort and cohort studies, lower
ORs were indeed found in cohorts for injection and transplantation. However, ORs for all other
procedures, as well as overall ORs, did not differ significantly between cohorts and non-cohorts,
supporting our choice to consider all study designs together. On the other hand, more than 50% of
studies included a potential risk of bias due to incomplete or missing use of adjustment variables when

estimating measures of association between HCV infection and iatrogenic procedures. Overall,
heterogeneity in measures associated with iatrogenic procedures was shown and may reveal potential
publication bias. In particular, non-significant risk measures might have been voluntarily neglected
resulting, again, in an overestimation of the risk associated with these two groups of procedures.

For some procedure groups, only few data were available, which led to important uncertainty in the
associated OR estimates. Half of procedure groups had less than ten risk measures, wound care being
the procedure for which this number was the lowest with only five studies. Also, some procedures like
surgery might have described operations during which multiple systematic procedures were
performed and not taken into account (pre-surgical anaesthesia, …). More generally, we rarely had
access to measures of risks associated with a unique realization of each procedure. Patients might have
undergone the same procedure multiple times but this information was not taken into account. In
particular, the risk of getting HCV infected during haemodialysis is highly related to the duration of
haemodialysis and the risk related to blood transfusion is somehow positively proportional to the
number of received transfusions.[96] These limitations may have caused overestimation of the risk
associated with hospital-based procedures.

In addition, the date of realization of a procedure was not always available, and some measures might
have been based on procedures performed a long time ago, thus leading again to an overestimation
of the risk. Indeed, we found the pooled OR of blood transfusions performed before 1998 to be higher
than the pooled OR of undated blood transfusions, strongly suggesting that the risk was higher for
older procedures - all the more so that the undated procedures could also have included old
procedures.

In conclusion, despite the uncertainty in our estimates and the probable decrease in the general risk
of HCV infection through hospital-based procedures over the last twenty years, this work shows that
healthcare settings remain an important gateway of HCV infection and underline the importance of
implementing efficient infection control.

Our results suggest a risk-based ranking for iatrogenic procedures, wound care being the most at-risk
procedure, and confirm the important role of blood screening in decreasing the risk of HCV infection.
We also show that the strength of association between HCV infection and iatrogenic procedures tend
to be higher in high prevalence countries. This could partly be explained by the high global
heterogeneity in infection and prevention control knowledge in healthcare workers, especially
concerning bloodborne pathogens.[97]

Two main tracks appear to be key to control HCV iatrogenic infections. First, knowledge of existing
infection control measures should be improved in order to make them fully effective. Second,
prevention efforts should be specifically targeted at high-risk procedures, such as wound care,
transplantation or procedures involving intravenous injection, and in high HCV prevalence settings. In
this regard, our work provides support to identify the procedures on which these efforts should be
focused. Our results may also prove useful for future modelling studies assessing the effectiveness of
control measures to limit HCV transmission in healthcare settings.

In 2016, the World Health Organization (WHO) set targets for global HCV elimination as a public health
problem by 2030 – an 80% reduction in incidence and a 65% reduction in mortality from 2015 levels.[98]
In order to reach these targets, high-prevalence countries such as Egypt and Pakistan have engaged in
elimination programmes based on large-scale test-and-treat campaigns.[99] By helping efficiently scale
up prevention interventions, our work has the potential to improve the cost-effectiveness of these
campaigns, reaching the WHO targets faster and more easily.

Contributors

PH, KJ and LT conceived the study, wrote the protocol and data analysis plan. PH and MC screened the articles and conflicts were resolved by LT and KJ. Clinical input and HCV expertise were provided by LBLN and YS. PH did the statistical analysis. PH, LT and KJ interpreted the data. PH wrote the first draft of the report with input from LT, KJ, MC, LBLN and YS. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. PH, KJ and LT accessed and verified the data.

Data sharing

Data summary will be available in the supplementary appendix. The statistical analysis plan will be available with publication upon reasonable request to the corresponding author.

Declaration of interests

We declare no competing interests.

Acknowledgements

This study was funded by INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hépatites), grant number 12320 B115.

References

1. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. *WJG* 2016; **22**: 7824.

2. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide: Liver cancer attributable to hepatitis viruses worldwide. *Int J Cancer* 2018; **142**: 2471–7.

3. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization, 2021 https://apps.who.int/iris/handle/10665/341412(accessed Oct 19, 2021).

4. Sapena V, Enea M, Torres F, *et al.* Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut* 2021; : gutjnl-2020-323663.

5. Latham NH, Doyle JS, Palmer AY, *et al.* Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. *Liver Int* 2019; **39**: 2244–60.

6. Nahon P, Layese R, Bourcier V, *et al.* Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. *Gastroenterology* 2018; **155**: 1436-1450.e6.

375 7.   Trickey A, Fraser H, Lim AG, *et al.* The contribution of injection drug use to hepatitis C virus
376   transmission globally, regionally, and at country level: a modelling study. *The Lancet*
377   *Gastroenterology & Hepatology* 2019; **4**: 435–44.
378

379 8.   Frank C, Mohamed MK, Strickland GT, *et al.* The role of parenteral antischistosomal therapy in
380   the spread of hepatitis C virus in Egypt. *The Lancet* 2000; **355**: 887–91.
381

382 9.   Sarman Singh, S. N. Dwivedi, Rita S. Hepatitis B, C and Human Immunodeficiency Virus
383   Infections in Multiply-injected Kala-azar Patients in Delhi. *Scandinavian Journal of Infectious*
384   *Diseases* 2000; **32**: 3–6.
385

386 10. Thompson ND. Nonhospital Health Care–Associated Hepatitis B and C Virus Transmission:
387   United States, 1998–2008. *Ann Intern Med* 2009; **150**: 33.
388

389 11. Alduraywish A, Ragheb M, Taher I, Louis N, Aldossari K, Kishk R. Prevalence, risk factors and
390   impact of occult HCV infection on liver morbidity among haemodialysis patients: hospital-
391   based cross-sectional study. *Scandinavian Journal of Gastroenterology* 2020; **55**: 963–9.
392
393

394 12. Arnold S, Melville SK, Morehead B, Vaughan G, Moorman A, Crist MB. *Notes from the Field:*
395   Hepatitis C Transmission from Inappropriate Reuse of Saline Flush Syringes for Multiple
396   Patients in an Acute Care General Hospital — Texas, 2015. *MMWR Morb Mortal Wkly Rep*
397   2017; **66**: 258–60.
398

399 13. El-Ghitany EM, Abdel Wahab MM, Abd El-Wahab EW, Hassouna S, Farghaly AG. A
400   comprehensive hepatitis C virus risk factors meta-analysis (1989-2013); Do they differ in
401   Egypt? *Liver Int* 2015; **35**: 489–501.
402

403 14. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia.
404   Available at www.covidence.org.
405

406 15. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial.
407   *Evid Based Mental Health* 2019; **22**: 153–60.
408

409 16. Médecins du Monde and Treatment Action Group. MapCrowd: online global data on hepatitis
410   C. Available at: https://mapcrowd.org/ (accessed Jul 19, 2021).
411

412 17. Fullman N, Yearwood J, Abay SM, *et al.* Measuring performance on the Healthcare Access and
413   Quality Index for 195 countries and territories and selected subnational locations: a systematic
414   analysis from the Global Burden of Disease Study 2016. *The Lancet* 2018; **391**: 2236–71.
415

416 18. Cochran WG. The comparison of percentages in matched samples. *Biometrika* 1950; **37**: 256–
417   66.
418

419 19. Lam J, Sutton P, Kalkbrenner A, *et al.* A Systematic Review and Meta-Analysis of Multiple
420   Airborne Pollutants and Autism Spectrum Disorder. *PLoS ONE* 2016; **11**: e0161851.
421

422 20. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
423   graphical test. *BMJ* 1997; **315**: 629–34.
424

21. AbdulQawi K, Youssef A, Metwally MA, Ragih I, AbdulHamid M, Shaheen A. Prospective study of prevalence and risk factors for hepatitis C in pregnant Egyptian women and its transmission to their infants. *Croat Med J* 2010; **51**: 219–28.

22. Akhtar AM, Khan MA, Ijaz T, *et al.* Hepatitis C virus infection in pregnant women in Lahore, Pakistan: An analytical cross-sectional study. *Int J Agric Biol* 2014; **16**: 160–4.

23. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. *Nephrology (Carlton, Vic)* 2003; **8**: 256–60.

24. Amin Elzorkany KM, Zahran A. Hepatitis C virus status in hemodialysis patients in Menoufia Government, Egypt, five years apart: Do we have any improvement? *Saudi J Kidney Dis Transpl* 2017; **28**: 1126–32.

25. Amjad U, Ahmad SQ, Mir S, Ayub M. Association of anti-HCV sero-prevalence with blood transfusion and practice of haemodialysis from multiple centres in patients on maintenance haemodialysis. *Pakistan Journal of Medical Sciences* 2020; **36**: 286–9.

26. Asad M, Ahmed F, Zafar H, Farman S. Frequency and determinants of hepatitis B and C virus in general population of Farash Town, Islamabad. *Pak J Med Sci* 2015; **31**: 1394–8.

27. Asemahagn MA. Epidemiology of hepatitis B and C virus infections among patients who booked for surgical procedures at Felegehiwot referral hospital, Northwest Ethiopia. *PloS one* 2020; **15**: e0234822.

28. Aslam A, Munawar I, Zahid N. Blood transfusion as a risk factor for hepatitis C in pregnancy. *Pak J Med Health Sci* 2016; **10**: 233–4.

29. Ba-Essa EM, Mobarak EI, Al-Daghri NM. Hepatitis C virus infection among patients with diabetes mellitus in Dammam, Saudi Arabia. *BMC health services research* 2016; **16**: 313.

30. Balew M, Moges F, Yismaw G, Unakal C. Assessment of hepatitis B virus and hepatitis C virus infections and associated risk factors in HIV infected patients at Debretabor hospital, South Gondar, Northwest Ethiopia. *Asian Pac J Trop Dis* 2014; **4**: 1–7.

31. Barut S, Barut S, Eğri M. Healthcare related risk factors account for the majority of HCV transmissions in middle black sea region of Turkey: A case-control study. *Turk Klinikleri J Med Sci* 2011; **31**: 142–7.

32. Beltrân M, Navas M-C, De La Hoz F, *et al.* Hepatitis C virus seroprevalence in multi-transfused patients in Colombia. *J Clin Virol* 2005; **34**: S33–8.

33. Bibi S, Dars S, Ashfaq S, Qazi RA, Akhund S. Seroprevalence and risk factors for hepatitis C virus (HCV) infection in pregnant women attending public sector tertiary care hospital in Hyderabad Sindh. *Pak J Med Sci* 2013; **29**.

34. Bouare B, Gothot A, Delwaide J, *et al.* Epidemiological profiles of human immunodeficiency virus and hepatitis C virus infections in malian women: Risk factors and relevance of disparities. *World J Hepatol* 2013; **5**: 196–205.

476   35. Calderon GM, Gonzalez-Velaquez F, Gonzalez-Bonilla CR, *et al.* Prevalence and risk factors of
477   hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused
478   recipients in Mexico. *Transfusion* 2009; **49**: 2200–7.
479
480   36. Calles DL, Collier MG, Khudyakov Y, *et al.* Hepatitis C virus transmission in a skilled nursing
481   facility, North Dakota, 2013. *American Journal of Infection Control* 2017; **45**: 126–32.
482
483   37. da Silva NM, Germano FN, Mendoza-Sassi RA, Seuánez HN, Soares MA, de Martinez AM.
484   Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions
485   in hemodialysis centers from southern Brazil. *Virology journal* 2013; **10**: 167.
486
487   38. De Oliveira AM, White KL, Leschinsky DP, *et al.* An outbreak of hepatitis C virus infections
488   among outpatients at a hematology/oncology clinic. *Ann Intern Med* 2005; **142**: 898-902+I –
489   38.
490
491   39. De Weggheleire A, An S, De Baetselier I, *et al.* A cross-sectional study of hepatitis C among
492   people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted
493   screening. *Plos One* 2017; **12**.
494
495   40. Doblali T, Bahadi A, El Amrani M, Benyahia M. Prevalence and risk factors of hepatitis c virus
496   infection in patients on hemodialysis: Results of a moroccan study. *Med Sante Tropica* 2014;
497   **24**: 375–8.
498
499   41. Ejeta E, Dabsu R. Prevalence of hepatitis C virus and HIV infection among pregnant women
500   attending antenatal care clinic in Western Ethiopia. *Front Med* 2019; **6**.
501
502   42. Flisiak R, Halota W, Horban A, Juszczyk J, Pawlowska M, Simon K. Prevalence and risk factors
503   of HCV infection in Poland. *Eur J Gastroenterol Hepatol* 2011; **23**: 1213–7.
504
505   43. Galperim B, Mattos AA, Stein AT, *et al.* Hepatitis C in hemodialysis: the contribution of injection
506   drug use. *Brazilian Journal of Infectious Diseases* 2010; **14**: 422–6.
507
508   44. Gasim GI, Hamdan HZ, Hamdan SZ, Adam I. Epidemiology of Hepatitis B and Hepatitis C Virus
509   Infections Among Hemodialysis Patients in Khartoum, Sudan. *Journal of Medical Virology* 2012;
510   **84**: 52–5.
511
512   45. Ghias M, Pewaiz MK, Marshall R, Thornley S. Identification of risk factors for Hepatitis C
513   infection in the Gujranwala District of Punjab, Pakistan. *World Appl Sci J* 2012; **20**: 94–101.
514
515   46. Haider J, Lufullah G, Nazli R, Akhtar T, Shah A. Screening of adult dental patients visiting Khyber
516   College of Dentistry, Peshawar for HBV and HCV infections and identifying the associated risk
517   factors. *Pak J Med Sci* 2017; **33**: 615–20.
518
519   47. Hutton J, Doyle J, Zordan R, *et al.* Point-of-care Hepatitis C virus testing and linkage to
520   treatment in an Australian inner-city emergency department. *Int J Drug Policy* 2019; **72**: 84–
521   90.
522
523   48. Ishikawa T, Fukushima Y, Shiobara Y, *et al.* Outbreak of hepatitis C virus infection in an
524   outpatient clinic. *Journal of gastroenterology and hepatology* 2005; **20**: 1087–93.
525
526   49. Jaffery T, Tariq N, Ayub R, Yawar A. Frequency of hepatitis C in pregnancy and pregnancy
527   outcome. *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP* 2005; **15**: 716–9.

50. Jamil Z, Waheed Y, Ahsan O, Najmi MH, Yousuf H. Familial clustering of hepatitis C virus in a Pakistani population. *J Med Virol* 2020; **92**: 3499–506.

51. Jimenez AP, Mohamed MK, Eldin NS, *et al.* Injection Drug Use Is a Risk Factor for HCV Infection in Urban Egypt. *Plos One* 2009; **4**.

52. Kandeel AM, Talaat M, Afifi SA, *et al.* Case control study to identify risk factors for acute hepatitis C virus infection in Egypt. *Bmc Infectious Diseases* 2012; **12**.

53. Khalid GG, Kyaw KWY, Bousquet C, *et al.* From risk to care: The hepatitis C screening and diagnostic cascade in a primary health care clinic in Karachi, Pakistan-a cohort study. *Int Health* 2019; **12**: 19–27.

54. Khan UR, Janjua NZ, Akhtar S, Hatcher J. Case-control study of risk factors associated with hepatitis C virus infection among pregnant women in hospitals of Karachi-Pakistan. *Tropical Medicine & International Health* 2008; **13**: 754–61.

55. Kim JY, Cho J, Hwang SH, *et al.* Behavioral and Healthcare-Associated Risk Factors for Chronic Hepatitis C Virus Infection in Korea. *Journal of Korean Medical Science* 2012; **27**: 1371–7.

56. Kundu A, Mehta S, Agrawal BK, Singh VA. Assessment of associated risk factors in hepatitis B virus and hepatitis C virus infections. *JK Science* 2017; **18**: 229–32.

57. Lioussfi Z, Errami Z, Radoui A, *et al.* Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. *Saudi J Kidney Dis Transpl* 2014; **25**: 672–9.

58. Loras C, Saro C, Gonzalez-Huix F, *et al.* Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: A nationwide, multicenter study. *Am J Gastroenterol* 2009; **104**: 57–63.

59. Metwally A, Mohsen A, Saleh R, *et al.* Prioritizing high-risk practices and exploring new emerging ones associated with hepatitis C virus infection in Egypt. *Iranian Journal of Public Health* 2014; **43**: 1385–94.

60. Mittal G, Gupta P, Thakuria B, Mukhiya GK, Mittal M. Profile of Hepatitis B Virus, Hepatitis C Virus, Hepatitis D Virus and Human Immunodeficiency Virus Infections in Hemodialysis Patients of a Tertiary Care Hospital in Uttarakhand. *J Clin Exp Hepatol* 2013; **3**: 24–8.

61. Mohd Suan MA, Said SM, Lim PY, Azman AZF, Abu Hassan MR. Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study. *PloS one* 2019; **14**: e0224459.

62. Mohsen A, Bernier A, Lefouler L, *et al.* Hepatitis C virus acquisition among Egyptians: Analysis of a 10-year surveillance of acute hepatitis C. *Trop Med Int Health* 2015; **20**: 89–97.

63. Mostafa A, Ebeid FSE, Khaled B, Ahmed RHM, El-Sayed MH. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies. *Trop Med Int Health* 2020; **25**: 850–60.

64. Murad EA, Babiker SM, Gasim GI, Rayis DA, Adam I. Epidemiology of hepatitis B and hepatitis C virus infections in pregnant women in Sana'a, Yemen. *BMC Pregnancy Childbirth* 2013; **13**.

65. Neumeister AS, Pilcher LE, Erickson JM, *et al.* Hepatitis-C prevalence in an urban native-American clinic: A prospective screening study. *Journal of the National Medical Association* 2007; **99**: 389–92.

66. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, *et al.* HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. *Gut* 2010; **59**: 1554–60.

67. Patil SR, Datkhile KD, Ghorpade MV, Patil SS, Kakade SV. Seroprevalence, risk factors and genotype distribution for Hepatitis C infection: A study from rural hospital in Maharashtra. *Indian journal of medical microbiology* 2017; **35**: 563–7.

68. Prasad M, Saade GR, Sandoval G, *et al.* Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors. *Obstetrics and gynecology* 2020; **135**: 778–88.

69. Qureshi H, Arif A, Riaz K, Alam SE, Ahmed W. Determination of risk factors for hepatitis B and C in male patients suffering from chronic hepatitis. *BMC Res Notes* 2009; **2**.

70. Ramsey SD, Unger JM, Baker LH, *et al.* Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection among Patients with Newly Diagnosed Cancer from Academic and Community Oncology Practices. *JAMA Oncol* 2019; **5**: 497–505.

71. Rosińska M, Parda N, Kołakowska A, *et al.* Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016. *PloS one* 2017; **12**: e0185055.

72. Ross RS, Viazov S, Clauberg R, *et al.* Lack of de novo hepatitis C virus infections and absence of nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients. *J Viral Hepatitis* 2009; **16**: 230–8.

73. Russmann S, Dowlatshahi EA, Printzen G, Habicht S, Reichen J, Zimmermann H. Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. *Bmc Gastroenterology* 2007; **7**.

74. Sahajian F, Vanhems P, Bailly F, Fabry J, Trepo C, Sepetjan M. Screening campaign of hepatitis C among underprivileged people consulting in health centres of Lyon area, France. *Eur J Public Health* 2007; **17**: 263–71.

75. Samimi-Rad K, Hosseini M, Mobeini G, *et al.* Hepatitis C virus infection among multi-transfused patients and personnel in haemodialysis units in central Islamic Republic of Iran. *East Mediterr Health J* 2012; **18**: 227–35.

76. Samimi-Rad K, Hosseini M, Shahbaz B. Hepatitis C virus infection and HCV genotypes of hemodialysis patients. *Iranian Journal of Public Health* 2008; **37**: 146–52.

77. Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. *Haemophilia* 2007; **13**: 156–63.

78. Schmidt AJ, Rockstroh JK, Vogel M, *et al.* Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study. *PloS one* 2011; **6**: e17781.

79. Senosy SA, El Shabrawy EM. Hepatitis C virus in patients on regular hemodialysis in Beni-Suef
Governorate, Egypt. *The Journal of the Egyptian Public Health Association* 2016; **91**: 86–9.

80. Seong MH, Kil H, Kim YS, *et al.* Clinical and epidemiological features of hepatitis C virus
infection in South Korea: a prospective, multicenter cohort study. *Journal of medical virology*
2013; **85**: 1724–33.

81. Shahriari-Fard F, Alavian SM, Farajzadegan Z, Rabiei A, Ataei B, Ataie M. Assessment of
hepatitis C risk factors in center of Iran: A case-control study. *J Res Med Sci* 2018; **23**.

82. Shimokura G, Chai F, Weber DJ, *et al.* Patient-care practices associated with an increased
prevalence of hepatitis c virus infection among chronic hemodialysis patients. *Infect Control*
Hosp Epidemiol 2011; **32**: 415–24.

83. Silva JL, de Souza VS, Vilella TA, Domingues AL, Coêlho MR. HBV and HCV serological markers
in patients with the hepatosplenic form of mansonic schistosomiasis. *Arquivos de*
gastroenterologia 2011; **48**: 124–30.

84. Sohn HS, Kim JR, Ryu SY, *et al.* Risk Factors for Hepatitis C Virus (HCV) Infection in Areas with
a. High Prevalence of HCV in the Republic of Korea in 2013. *Gut and Liver* 2016; **10**: 126–32.

85. Somi MH, Etemadi J, Ghojazadeh M, *et al.* Risk factors of HCV seroconversion in hemodialysis
patients in Tabriz, Iran. *Hepatitis Mon* 2014; **14**.

86. Su Y, Yan R, Duan Z, *et al.* Prevalence and risk factors of hepatitis C and B virus infections in
hemodialysis patients and their spouses: A multicenter study in Beijing, China. *J Med Virol*
2013; **85**: 425–32.

87. Taye M, Daka D, Amsalu A, Hussen S. Magnitude of hepatitis B and C virus infections and
associated factors among patients scheduled for surgery at Hawassa University
comprehensive specialized Hospital, Hawassa City, southern Ethiopia. *BMC Res Notes* 2019;
12.

88. Ullah M, Hasan F, Najmudin, *et al.* Seroprevalence of Hepatitis C virus infection in Kohat
division, Khyber Pakhtoonkhwa, Pakistan. *Pak J Zool* 2016; **48**: 1721–5.

89. Ver Hoeve E, Codlin AJ, Jawed F, *et al.* Persisting role of healthcare settings in hepatitis C
transmission in Pakistan: cause for concern. *Epidemiology and infection* 2013; **141**: 1831–9.

90. Vidales-Braz BM, Da Silva NMO, Lobato R, *et al.* Detection of hepatitis C virus in patients with
terminal renal disease undergoing dialysis in southern Brazil: Prevalence, risk factors,
genotypes, and viral load dynamics in hemodialysis patients. *Virol J* 2015; **12**.

91. Weisbord JS, Trepka MJ, Zhang G, Smith IP, Brewer T. Prevalence of and risk factors for
hepatitis C virus infection among STD clinic clientele in Miami, Florida. *Sexually transmitted*
infections 2003; **79**: E1.

92. Pozzetto B, Memmi M, Garraud O, Roblin X, Berthelot P. Health care-associated hepatitis C
virus infection. *World J Gastroenterol* 2014; **20**: 17265–78.

93. World Health Organization. Blood safety and availability (fact sheet, 2021). Retrieved from:
https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability

686
687   94. Defendorf CM, Paul S, Scott GJ. Iatrogenic Hepatitis C Virus Transmission and Safe Injection
688   Practices. *J Am Osteopath Assoc* 2018; **118**: 311.
689
690   95. Morris J, Duckworth GJ, Ridgway GL. Gastrointestinal endoscopy decontamination failure and
691   the risk of transmission of blood-borne viruses: a review. *Journal of Hospital Infection* 2006;
692   **63**: 1–13.
693
694   96. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures:
695   A global review. *Journal of Hepatology* 2006; **45**: 607–16.
696
697   97. Alhumaid S, Al Mutair A, Al Alawi Z, *et al.* Knowledge of infection prevention and control among
698   healthcare workers and factors influencing compliance: a systematic review. *Antimicrob Resist*
699   *Infect Control* 2021; **10**: 86.
700
701   98. World Health Organization. (2016). Global health sector strategy on viral hepatitis 2016-2021.
702   Towards   ending   viral   hepatitis.   World   Health   Organization.
703   https://apps.who.int/iris/handle/10665/246177 (accessed Oct 19, 2021)
704
705
706   99. Lim AG, Qureshi H, Mahmood H, *et al.* Curbing the hepatitis C virus epidemic in Pakistan: the
707   impact of scaling up treatment and prevention for achieving elimination. *International*
708   *Journal of Epidemiology* 2018; **47**: 550–60.

731 **FIGURES AND CAPTIONS**

734
735
736 *Figure 1*: **Study selection**

739 *Figure 2*: **Study characteristics. .** Number of included studies by: (a) year of publication; (b) type
740 of patients; (c) country; (d) Study designs.

Figure 3: **Forest plot reporting pooled OR estimates for HCV infection risk associated with**
different groups of iatrogenic procedures. Points correspond to average estimates and error
bars correspond to 95% CI of these estimates. The solid line represents the limit for which OR
= 1 and the dotted line the value of the overall estimate. The total number of observations
used for each pooled OR calculation is specified in the column *N* and represented as the size
of the grey area around each point estimate; the heterogeneity for each estimation is depicted
in the column *I²*. A given study could be used in the OR estimation of multiple procedures
groups. Procedures are sorted based on the value of their associated mean estimate, from the
highest to the lowest.

775
776

778   ***Figure 4*: Maps of risks of HCV infection for: (a) Blood transfusion (b) Surgery in various**
779   **countries.** Brown points correspond to the number of observations used to compute a given
780   pooled OR. Each country is coloured based on the value of the estimated OR following a light
781   red to dark red colour gradient. Values of average estimates are reported as well as their 95%
782   CI.

Figure 5: **Forest plot reporting pooled OR estimates for HCV infection risk associated with different groups of iatrogenic procedures for high HCV prevalence countries (>5%) vs. low HCV prevalence countries (<5%)**. The high prevalence group includes Egypt, Pakistan and Mali. Points correspond to average estimates and error bars correspond to 95% CI of these estimates. The solid line represents the limit for which OR = 1 and the dotted line the average value of the overall estimate. The total number of observations used for each pooled OR calculation is specified in the column *N* and the heterogeneity for each estimation is depicted in the column I^2. A given study could be used in the OR estimation of multiple procedures groups. Procedures are sorted based on the value of their associated mean estimate, from the highest to the lowest. There was no measure reported for transplantation in high HCV prevalence countries. *: procedures for which a significant different was found between high and low prevalence countries; Blanks within the I^2 column correspond to absence of heterogeneity because of procedure group counting only one observation.

817 **TABLE AND CAPTION**

819 *Table 1*: **Aggregation of procedures found within selected articles.** Procedure names are reported as
820 mentioned in each of the articles.

Group	Procedures within group
Surgery	Surgery, operation, bloody operation, splenectomy, laparoscopy, organ biopsy, biopsy, ligation of oesophageal varices, caesarean section
Transplantation	Transplantation, renal transplantation
Blood transfusion	dated blood transfusion / non-dated blood transfusion
Intravenous (IV) / Catheter	Cholangiography, IV pyelography, IV injection, IV-line, sclerotherapy, catheter, central venous catheter, cannula, phlebotomy
Haemodialysis	Haemodialysis
Wound care	Wound suture, wound care
Injection	IM injection, percutaneous injection, subcutaneous injection, injection/vaccination, injection
Other procedures	EMG, haemorrhoids treatment, tapping ascites, abscess drainage, abortion
Endoscopy	Endoscopy, colonoscopy, gastroscopy
Dental care	Tooth extraction, dental anaesthesia, dental procedure, dental care, tooth filling

821